TAC-101

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, Taiho Oncology, Inc.

Conditions

Advanced Hepatocellular CarcinomaHepatocellular CarcinomaLiver Cancer

Phase 1

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

CompletedNCT00077142

M.D. Anderson Cancer CenterLiver Cancer

Start: 2001-04-30End: 2005-08-31Updated: 2018-10-31

Phase 2

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

TerminatedNCT00667628

Taiho Oncology, Inc.Advanced Hepatocellular Carcinoma

Start: 2008-04-24End: 2009-12-22Updated: 2024-09-19

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

TerminatedNCT00687596

Taiho Oncology, Inc.Hepatocellular Carcinoma

Start: 2008-08-01End: 2010-05-10Updated: 2024-09-19

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

WithdrawnNCT00756782

Taiho Oncology, Inc.Advanced Hepatocellular Carcinoma

Start: 2008-10-31End: 2008-12-31Updated: 2024-09-04